Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
167.23
+0.85 (0.51%)
Mar 3, 2026, 12:10 PM EST - Market open
Axsome Therapeutics Employees
Axsome Therapeutics had 925 employees as of December 31, 2025. The number of employees increased by 242 or 35.43% compared to the previous year.
Employees
925
Change
242
Growth
35.43%
Revenue / Employee
$690,266
Profits / Employee
-$198,026
Market Cap
8.55B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 925 | 242 | 35.43% |
| Sep 30, 2025 | 816 | 209 | 34.43% |
| Jun 30, 2025 | 846 | 257 | 43.63% |
| Mar 31, 2025 | 712 | 143 | 25.13% |
| Dec 31, 2024 | 683 | 138 | 25.32% |
| Sep 30, 2024 | 607 | 105 | 20.92% |
| Jun 30, 2024 | 589 | 167 | 39.57% |
| Mar 31, 2024 | 569 | 176 | 44.78% |
| Dec 31, 2023 | 545 | 162 | 42.30% |
| Sep 30, 2023 | 502 | 150 | 42.61% |
| Jun 30, 2023 | 422 | 224 | 113.13% |
| Mar 31, 2023 | 393 | 277 | 238.79% |
| Dec 31, 2022 | 383 | 275 | 254.63% |
| Sep 30, 2022 | 352 | 246 | 232.08% |
| Jun 30, 2022 | 198 | 105 | 112.90% |
| Mar 31, 2022 | 116 | 46 | 65.71% |
| Dec 31, 2021 | 108 | 48 | 80.00% |
| Sep 30, 2021 | 106 | 53 | 100.00% |
| Jun 30, 2021 | 93 | 50 | 116.28% |
| Mar 31, 2021 | 70 | 25 | 55.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Madrigal Pharmaceuticals | 915 |
| Arrowhead Pharmaceuticals | 711 |
| Vaxcyte | 507 |
| Cytokinetics | 498 |
| Halozyme Therapeutics | 423 |
| Krystal Biotech | 295 |
| Nuvalent | 228 |
AXSM News
- 6 days ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 days ago - Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued - Seeking Alpha
- 8 days ago - Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 14 days ago - Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd. - GlobeNewsWire
- 5 weeks ago - Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 - GlobeNewsWire
- 5 weeks ago - Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline - Seeking Alpha
- 7 weeks ago - MoneyShow's Best Investment Ideas For 2026: Part 2 - Seeking Alpha